Stephen Webster - Viking Therapeutics Independent Director
| VKTX Stock | USD 75.76 0.67 0.88% |
Director
Mr. Stephen W. Webster is Independent Director of the Company. Mr. Webster has served as a member of our Board since May 2014. Mr. Webster has served as the Chief Financial Officer of Spark Therapeutics, Inc., a biotechnology company, since July 2014. He was previously SVP and Chief Financial Officer of Optimer Pharmaceuticals, Inc., a biotechnology company, from 2012 to 2013, until its acquisition by Cubist Pharmaceuticals, Inc. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporationrationration, a biopharmaceutical company, from June 2008 until its acquisition by Cubist Pharmaceuticals, Inc. in December 2011. From 2007 until joining Adolor Corporation in 2008, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. . Mr. Webster previously served as cofounder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. From 1987 to 2000, Mr. Webster served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. He has served as a Director of Nabriva Therapeutics plc since August 2016 since 2014.
| Age | 57 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Stephen Webster Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Webster against Viking Therapeutics stock is an integral part of due diligence when investing in Viking Therapeutics. Stephen Webster insider activity provides valuable insight into whether Viking Therapeutics is net buyers or sellers over its current business cycle. Note, Viking Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Viking Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Webster over three months ago Purchase by Stephen Webster of 1200 shares of Luxfer Holdings | ||
Stephen Webster over six months ago Exercise or conversion by Stephen Webster of 800 shares of Luxfer Holdings subject to Rule 16b-3 | ||
Stephen Webster over a year ago Payment of 635 shares by Stephen Webster of Spark Therapeutics subject to Rule 16b-3 |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1278) % which means that it has lost $0.1278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1755) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 385.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robertson Gilliland | Adial Pharmaceuticals | 37 | |
| Gregory French | Pulmatrix | 53 | |
| Valier Boivin | Acasti Pharma | N/A | |
| Katherine Crewe | Acasti Pharma | N/A | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Kurt Graves | Pulmatrix | 47 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Jean Belanger | Acasti Pharma | N/A | |
| Jonathan Siegel | Jaguar Animal Health | 44 | |
| JeanDaniel Belanger | Acasti Pharma | N/A | |
| Akihisa Akao | Pulmatrix | 59 | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
| John Micek | Jaguar Animal Health | 64 | |
| Terrance McGuire | Pulmatrix | 61 | |
| Folkert Kamphuis | Jaguar Animal Health | 57 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Rowland, Director | ||
| Kathy Rouan, Director | ||
| Matthew Singleton, Independent Director | ||
| Stephanie Diaz, IR Contact Officer | ||
| Marianne Mancini, Chief Officer | ||
| Greg Zante, Vice President Finance & Operartions | ||
| Stephen Webster, Independent Director | ||
| Rochelle Hanley, Chief Medical Officer | ||
| Catherine Kelleher, Vice President - Clinical Development | ||
| Lawson Macartney, Independent Director | ||
| Michael Morneau, Vice Administration | ||
| Amy Broidrick, Senior Vice President - Corporate Development | ||
| Hiroko Masamune, Chief Development Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations | ||
| Matthew Foehr, Director |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 7.47 B | ||||
| Shares Outstanding | 110.27 M | ||||
| Shares Owned By Insiders | 6.03 % | ||||
| Shares Owned By Institutions | 72.46 % | ||||
| Number Of Shares Shorted | 11.15 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 21.71 X | ||||
| EBITDA | (100.83 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Viking Stock analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Viking Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viking Therapeutics. If investors know Viking will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viking Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Return On Assets (0.13) | Return On Equity (0.18) |
The market value of Viking Therapeutics is measured differently than its book value, which is the value of Viking that is recorded on the company's balance sheet. Investors also form their own opinion of Viking Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viking Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viking Therapeutics' market value can be influenced by many factors that don't directly affect Viking Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viking Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viking Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viking Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.